ByTrending Posts
Will Big Pharma’s Billion-Dollar AI Investments Reshape the…
Key Highlights The AI Investment Race Has Officially Begun Artificial intelligence has rapidly evolved from an experimental technology…
Can Bristol Myers Squibb’s Enterprise-Wide Rollout of Anthropic’s…
Key Highlights From AI Investment to Business Value Creation Bristol Myers Squibb’s enterprise-wide adoption of Anthropic’s Claude represents…
Can Edison Scientific and Population Health Partners’ AI…
Key Highlights The Deal at a Glance Announced on June 29, 2026, the partnership pairs PHP’s proven track…
Can a $2.5 Billion AI Alliance Between Insilico…
Key Highlights The Deal at a Glance Announced at the BIO 2026 International Convention, the collaboration grants Insilico…
Can Sanofi SA’s New AI-Enabled Innovation Hub in…
Key Highlights: AI-Integrated Innovation Hubs Redefine Global R&D ModelsSanofi SA’s launch of its innovation and operations centre in…
Can Sanofi SA’s $1.2 Billion AI-Driven Autoimmune Alliance…
Key Highlights: AI-Powered Biologics Platforms Accelerate Next-Gen Antibody DiscoverySanofi SA’s licensing agreement with Kali Therapeutics Inc highlights the…
Can Eli Lilly and Company’s “Triple-G” AI-Enabled Next-Gen…
Key Highlights: AI-Driven Clinical Design Unlocks Superior Metabolic OutcomesEli Lilly and Company’s late-stage trial results for retatrutide highlight…
Can Novartis AG’s $3 Billion AI-Driven Oncology Bet…
Key Highlights: AI-Led Drug Discovery Accelerates Target Identification and ValidationNovartis AG’s acquisition of SNV4818 from Synnovation Therapeutics, Inc.…
How Will Emerging Drug Pricing Policies Reshape the…
The global biopharmaceutical industry is entering a new policy-driven era as governments intensify efforts to control drug costs,…
Trending Posts
Latest Stories
Will Big Pharma’s Billion-Dollar AI Investments Reshape the US$2 Trillion Pharmaceutical Industry Faster Than the Next Blockbuster Drug?
Key Highlights The AI Investment Race Has Officially Begun Artificial intelligence has rapidly evolved from…
Can Bristol Myers Squibb’s Enterprise-Wide Rollout of Anthropic’s Claude to 30,000 Employees Unlock Billions in AI-Driven Value and Redefine Biopharma’s Digital Future?
Key Highlights From AI Investment to Business Value Creation Bristol Myers Squibb’s enterprise-wide adoption of…
Can Edison Scientific and Population Health Partners’ AI Build the Next $10 Billion Biotech?
Key Highlights The Deal at a Glance Announced on June 29, 2026, the partnership pairs…
Can a $2.5 Billion AI Alliance Between Insilico Medicine and SK Biopharmaceuticals Rewrite the Future of Neuroimmune Drug Discovery?
Key Highlights The Deal at a Glance Announced at the BIO 2026 International Convention, the…
Gallery
